Paper Chase is a research database designed to offer abstracts of research articles published in journals that have a highly rated impact factor as determined by ISI Impact Factor and PageRank. Abstracts are organized by date, with the most recently published papers listed first. 

Paper Chase

221.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

Lancet.
Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, Gallant JE, Liu HC, Zhong L, Yale K, White K, Kearney BP, Szwarcberg J, Quirk E, Cheng AK, Akil B.
| Jun 30, 2012
222.

Pulmonary embolism and deep vein thrombosis.

Lancet.
Goldhaber SZ, Bounameaux H.
| May 12, 2012
223.

Are we ready to recommend aspirin for cancer prevention?

Lancet.
Chan AT, Cook NR.
| Apr 28, 2012
224.

Towards regenerative therapy for cardiac disease.

Lancet.
Ptaszek LM, Mansour M, Ruskin JN, Chien KR.
| Mar 10, 2012
225.

Improving medication safety.

Lancet.
Schnipper JL, Rothschild JM.
| Apr 07, 2012
226.

Survival of children with burn injuries.

Lancet.
Tompkins RG.
| Mar 17, 2012
227.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Lancet.
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M, Lerzo G.
| Feb 18, 2012
228.

β-agonists for ARDS: the dark side of adrenergic stimulation?

Lancet.
Thompson BT.
| Jan 21, 2012
229.

Bioartificial tissues and organs: are we ready to translate?

Lancet.
Ott HC, Mathisen DJ.
| Dec 10, 2011
230.

Statins and safety: can we finally be reassured?

Lancet.
Kohli P, Cannon CP.
| Dec 10, 2011
231.

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

Lancet.
Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C.
| Jan 07, 2012
232.

Medical complications associated with earthquakes.

Lancet.
Bartels SA, VanRooyen MJ.
| Feb 25, 2012
233.

Aspirin and colorectal cancer prevention in Lynch syndrome.

Lancet.
Chan AT, Lippman SM.
| Dec 17, 2011
234.

Time for zero deaths from tuberculosis.

Lancet.
Keshavjee S, Harrington M, Gonsalves G, Chesire L, Farmer PE.
| Oct 22, 2011
235.

A global scope for global health--including mental health.

Lancet.
Raviola G, Becker AE, Farmer P.
| Nov 05, 2011
236.

Accurate hypertension diagnosis is key in efficient control.

Lancet.
Gaziano TA.
| Oct 01, 2011
237.

Folate and cardiovascular disease: one size does not fit all.

Lancet.
Rimm EB, Stampfer MJ.
| Aug 13, 2011
239.

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.

Lancet.
Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS, Skyler JS.
| Jul 30, 2011
240.

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.

Lancet.
Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG, Lenhard J.
| Aug 06, 2011